HC Wainwright Reaffirms Buy Rating for Evotec (NASDAQ:EVO)

Evotec (NASDAQ:EVO)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 181.69% from the company’s current price.

Several other equities research analysts have also recently issued reports on EVO. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a report on Wednesday, July 15th. Weiss Ratings cut shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 25th. Finally, Berenberg Bank cut shares of Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.00.

Evotec Stock Performance

Shares of NASDAQ:EVO traded down $0.01 during trading on Wednesday, reaching $1.42. 123,975 shares of the stock traded hands, compared to its average volume of 103,110. The stock has a 50-day moving average of $1.77 and a two-hundred day moving average of $2.36. Evotec has a 52-week low of $1.33 and a 52-week high of $4.27. The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Apollon Wealth Management LLC purchased a new position in shares of Evotec during the 1st quarter worth $28,000. SmartHarvest Portfolios LLC purchased a new stake in Evotec in the first quarter worth about $44,000. Optiver Holding B.V. increased its position in Evotec by 598.4% in the first quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock worth $709,000 after buying an additional 242,973 shares in the last quarter. Finally, WCM Investment Management LLC increased its position in Evotec by 12.1% in the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after buying an additional 67,917 shares in the last quarter. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Key Headlines Impacting Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Evotec reported preliminary nine-month revenue and adjusted EBITDA above market expectations, prompting coverage describing the company as being on a potential recovery track. The update suggests improving execution and could support confidence in the biotechnology services provider’s turnaround. Evotec shares jump after preliminary 9-month revenue, EBITDA top estimates
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $4.00 price target, implying substantial upside from current trading levels. The target reflects expectations that improving financial performance could lead to a revaluation of EVO shares. HC Wainwright reaffirms buy rating and price target
• Positive Sentiment: Evotec appointed Dr. Joanna Holbrook as chief scientific officer and a member of the management board, effective November 1, 2026. Her more than 25 years of experience across pharma, biotechnology and academia is expected to strengthen Evotec’s global scientific strategy, technology platforms and proprietary drug-development efforts. Evotec appoints Dr. Joanna Holbrook as chief scientific officer
• Neutral Sentiment: The preliminary nine-month figures are encouraging, but they are not yet full reported results. Investors will likely focus on the detailed release, management’s outlook and evidence that the earnings improvement can continue.
• Negative Sentiment: Although the stock has decreased today, its recent weakness and position near a 12-month low indicate that investors remain concerned about Evotec’s ability to sustain a turnaround. The wide gap between the current share price and the $4.00 target also underscores the market’s continued skepticism.

About Evotec

Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Founded in 1993, the company supports programs from early-stage research through preclinical and clinical development, with expertise in small-molecule and biologic therapies.

Its activities include target identification and validation, screening, medicinal chemistry, pharmacology, drug manufacturing support and development services.